Search: onr:"swepub:oai:DiVA.org:uu-439205" >
Characteristics and...
Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy : a report from the Australasian Lymphoma Alliance
-
- Harwood, Matthew (author)
- Gold Coast Univ Hosp, Southport, Qld, Australia
-
- Hodges, Georgina (author)
- Townsville Univ Hosp, Townsville, Qld, Australia
-
- Tan, Xuan (author)
- Sir Charles Gairdner Hosp, Nedlands, WA, Australia; Univ Western Australia, Sch Med, Perth, Australia
-
show more...
-
- Cheah, Chan Y. (author)
- Sir Charles Gairdner Hosp, Nedlands, WA, Australia; Univ Western Australia, Sch Med, Perth, Australia
-
- Lim, Kenneth (author)
- St Vincents Hosp Melbourne, Fitzroy, Vic, Australia
-
- Ku, Matthew (author)
- St Vincents Hosp Melbourne, Fitzroy, Vic, Australia; Univ Melbourne, Sch Med, Fitzroy, Vic, Australia
-
- Tam, Constantine (author)
- St Vincents Hosp Melbourne, Fitzroy, Vic, Australia
-
- Lagerlöf, Ingemar (author)
- Uppsala universitet,Experimentell och klinisk onkologi
-
- Cochrane, Tara (author)
- Gold Coast Univ Hosp, Southport, Qld, Australia; Griffith Univ, Sch Med, Southport, Qld, Australia
-
show less...
-
(creator_code:org_t)
- 2020-08-28
- 2020
- English.
-
In: Leukemia and Lymphoma. - : Informa UK Limited. - 1042-8194 .- 1029-2403. ; 61:14, s. 3412-3416
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- The optimal management of the small number of patients who experience early failure of eBEACOPP in Hodgkin lymphoma (HL) is unclear. We identified 12 patients with HL who progressed within 12 months of the front-line therapy between January 2010 and July 2019. Median time of first progression following diagnosis was 7 months (range 2.1-13.2). Nine patients proceeded to stem cell therapy following salvage therapy (8 autografts, 1 allograft). Seven patients received novel therapy after relapse, of these, 6 were alive at census, versus 2 out of 5 of those who had standard therapy alone. At the end of follow up (median 22 months), 4 were deceased from progressive disease, 6 were in complete remission and 2 in partial remission on continuing therapy. The outcome of patients with primary refractory HL to eBEACOPP therapy is better than expected and the use of a novel agents after relapse may be a contributing factor.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Keyword
- Lymphoma and Hodgkin disease
- immunotherapy
- chemotherapeutic approaches
- eBEACOPP
- relapsed
- refractory
- novel
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database